Physician profile
David Parker
NPI 1558321729
$4,228.37
in general payments reported to CMS, 2019-2025
15 companies · $252 in 2025
The $252 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,715 · 2020: $218 · 2021: $367 · 2022: $545 · 2023: $802 · 2024: $330 · 2025: $252.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $500.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.85 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $500.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopervision INC. | $1,487.23 | 2019-2024 | Misight Contact Lens, Clariti Contact Lens |
| Alcon Vision LLC | $1,399.96 | 2019-2025 | Total30, Precision7, Rhopressa |
| Bausch & Lomb Americas INC. | $289.81 | 2022-2025 | Infuse, Vyzulta, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $171.89 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $140.57 | 2019-2022 | |
| Johnson & Johnson Vision Care, INC. | $133.46 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $125.00 | 2021 | |
| Sight Sciences, INC. | $113.85 | 2022 | |
| Optos, INC. | $93.65 | 2020 | |
| Shire North American Group INC | $74.11 | 2019 | |
| Carl Zeiss Meditec USA, INC. | $69.67 | 2022 | |
| Novartis Pharmaceuticals Corporation | $53.54 | 2021-2023 | |
| Allergan, INC. | $29.09 | 2020-2021 | |
| Dompe US, INC. | $27.03 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $19.51 | 2024 | Xdemvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.